Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by New South Capital Management Inc.

New South Capital Management Inc. lifted its stake in Royalty Pharma plc (NASDAQ:RPRX) by 19.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,957,125 shares of the biopharmaceutical company’s stock after purchasing an additional 490,754 shares during the quarter. Royalty Pharma accounts for about 3.2% of New South Capital Management Inc.’s investment portfolio, making the stock its 7th largest holding. New South Capital Management Inc. owned 0.50% of Royalty Pharma worth $75,436,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of RPRX. Swedbank AB boosted its position in shares of Royalty Pharma by 2.0% in the 3rd quarter. Swedbank AB now owns 11,027,370 shares of the biopharmaceutical company’s stock valued at $311,964,000 after purchasing an additional 213,900 shares during the period. Van ECK Associates Corp boosted its position in shares of Royalty Pharma by 171.1% in the 3rd quarter. Van ECK Associates Corp now owns 101,500 shares of the biopharmaceutical company’s stock valued at $2,777,000 after purchasing an additional 64,057 shares during the period. Robeco Institutional Asset Management B.V. boosted its position in shares of Royalty Pharma by 48.7% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 504,835 shares of the biopharmaceutical company’s stock valued at $14,282,000 after purchasing an additional 165,440 shares during the period. Asset Management One Co. Ltd. boosted its position in Royalty Pharma by 4.2% during the 3rd quarter. Asset Management One Co. Ltd. now owns 148,356 shares of the biopharmaceutical company’s stock worth $4,197,000 after acquiring an additional 5,942 shares during the period. Finally, River Road Asset Management LLC boosted its position in Royalty Pharma by 9.8% during the 3rd quarter. River Road Asset Management LLC now owns 469,980 shares of the biopharmaceutical company’s stock worth $13,296,000 after acquiring an additional 41,918 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Ratings Changes

Separately, TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $41.60.

Royalty Pharma Trading Up 1.4 %

Shares of NASDAQ RPRX opened at $33.77 on Thursday. Royalty Pharma plc has a one year low of $24.05 and a one year high of $34.20. The firm has a market capitalization of $19.47 billion, a PE ratio of 23.29, a PEG ratio of 2.31 and a beta of 0.47. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The business has a 50-day moving average price of $30.57 and a two-hundred day moving average price of $28.32.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. As a group, analysts predict that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 21st will be issued a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a dividend yield of 2.61%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Friday, February 21st. Royalty Pharma’s payout ratio is currently 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.